This site is intended for U.S. Healthcare Professionals only.

In vitro data—INFORM
surveillance study

In vitro activity does not necessarily correlate with clinical efficacy results. In a Phase 3 trial of cIAI patients, AVYCAZ plus metronidazole was noninferior to meropenem with regard to the overall clinical cure rate. Please see below for clinical results by pathogen.

International Network For Optimal Resistance Monitoring (INFORM)1

  • This 2015 US study surveyed the in vitro activity of AVYCAZ and many comparator agents against Gram-negative organisms from 68 medical centers distributed across all 9 US Census regions1
  • A total of 12,250 organisms were collected and tested, including 8793 Enterobacteriaceae and 1809 Pseudomonas aeruginosa strains, among others1
  • For AVYCAZ, FDA susceptibility breakpoints for Enterobacteriaceae (minimum inhibitory concentration [MIC] ≤8/4 mg/L) and P. aeruginosa (MIC ≤8/4 mg/L) were used2
  • For meropenem, 2016 CLSI susceptibility breakpoints for Enterobacteriaceae (MIC ≤1 μg/mL) and P. aeruginosa (MIC ≤2 μg/mL) were used3

CLSI, Clinical and Laboratory Standards Institute.

Bar graph showing Avycaz demonstrated >99% susceptibility against Enterobacteriaceae, including isolates producing ESBLs

*Of the 8793 Enterobacteriaceae isolates collected and tested, 868 were ESBL producers.1

ESBL, extended-spectrum β-lactamase.

Bar graph showing Avycaz demonstrated >99% susceptibility against K. pneumoniae, including isolates producing ESBLs

Of the 1724 K. pneumoniae isolates collected and tested, 274 were ESBL producers.1

Bar graph of data on AVYCAZ demonstrating >99% susceptibility against E.coli and isolates producing ESBLs

Of the 3376 E. coli isolates collected and tested, 511 were ESBL producers.1

Bar graph of data on how AVYCAZ demonstrated 98% susceptibility against P. aeruginosa

Phase 3 cIAI clinical data by pathogen

Chart of susceptibility to AVYCAZ demonstrated against Enterobacteriaceae, ESBL-producing isolates, and P.aeruginosa

TOC, test of cure.

mMITT, microbiologically modified intent-to-treat.